GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (TSX:HLS) » Definitions » Cyclically Adjusted PS Ratio

HLS Therapeutics (TSX:HLS) Cyclically Adjusted PS Ratio : 0.84 (As of May. 28, 2024)


View and export this data going back to 1959. Start your Free Trial

What is HLS Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-05-28), HLS Therapeutics's current share price is C$3.70. HLS Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was C$4.40. HLS Therapeutics's Cyclically Adjusted PS Ratio for today is 0.84.

The historical rank and industry rank for HLS Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

TSX:HLS' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.36   Med: 2.06   Max: 4.57
Current: 0.88

During the past years, HLS Therapeutics's highest Cyclically Adjusted PS Ratio was 4.57. The lowest was 0.36. And the median was 2.06.

TSX:HLS's Cyclically Adjusted PS Ratio is ranked better than
74.7% of 743 companies
in the Drug Manufacturers industry
Industry Median: 2.09 vs TSX:HLS: 0.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

HLS Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was C$0.529. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is C$4.40 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


HLS Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for HLS Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Cyclically Adjusted PS Ratio Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.81 3.57 3.03 2.11 0.89

HLS Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.26 1.10 0.89 0.91

Competitive Comparison of HLS Therapeutics's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Cyclically Adjusted PS Ratio falls into.



HLS Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

HLS Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=3.70/4.4
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HLS Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, HLS Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.529/126.2576*126.2576
=0.529

Current CPI (Mar. 2024) = 126.2576.

HLS Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.983 99.473 1.248
201409 1.084 99.394 1.377
201412 1.218 98.367 1.563
201503 0.000 99.789 0.000
201506 0.000 100.500 0.000
201509 0.000 100.421 0.000
201512 0.000 99.947 0.000
201603 0.000 101.054 0.000
201606 0.000 102.002 0.000
201609 0.000 101.765 0.000
201612 5.553 101.449 6.911
201703 0.000 102.634 0.000
201706 0.000 103.029 0.000
201709 0.000 103.345 0.000
201712 3.495 103.345 4.270
201803 0.662 105.004 0.796
201806 0.780 105.557 0.933
201809 0.729 105.636 0.871
201812 0.820 105.399 0.982
201903 0.645 106.979 0.761
201906 0.636 107.690 0.746
201909 0.578 107.611 0.678
201912 0.594 107.769 0.696
202003 0.546 107.927 0.639
202006 0.538 108.401 0.627
202009 0.547 108.164 0.639
202012 0.665 108.559 0.773
202103 0.564 110.298 0.646
202106 0.570 111.720 0.644
202109 0.590 112.905 0.660
202112 0.619 113.774 0.687
202203 0.568 117.646 0.610
202206 0.613 120.806 0.641
202209 0.646 120.648 0.676
202212 0.658 120.964 0.687
202303 0.624 122.702 0.642
202306 0.674 124.203 0.685
202309 0.673 125.230 0.679
202312 0.663 125.072 0.669
202403 0.529 126.258 0.529

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


HLS Therapeutics  (TSX:HLS) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


HLS Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (TSX:HLS) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.
Executives
Polar Asset Management Partners Inc. 10% Security Holder

HLS Therapeutics (TSX:HLS) Headlines

No Headlines